Increased uric acid levels are seen in which glycogen storage disease ?
Glucose oxidase converts glucose to?
Apoenzyme is ?
Fluoroacetate inhibits?
Which of the following is required for fatty acid synthesis ?
Which hormone inhibits hormone-sensitive lipase?
What is the characteristic nitrogenous product of lecithin hydrolysis?
What is the cofactor required for the enzyme xanthine oxidase?
NADH via glycerophosphate shunt makes how many ATP?
Which of the following pairs of compounds has the highest standard reduction potential?
NEET-PG 2012 - Biochemistry NEET-PG Practice Questions and MCQs
Question 31: Increased uric acid levels are seen in which glycogen storage disease ?
- A. Type I (Von Gierke's disease) (Correct Answer)
- B. Type II (Pompe disease)
- C. Type IV (Andersen disease)
- D. Type III (Cori disease)
Explanation: ***Type I (Von Gierke's disease)*** - In **Von Gierke's disease**, the deficiency of **glucose-6-phosphatase** leads to accumulation of glucose-6-phosphate in hepatocytes. - **Hyperuricemia** occurs due to: 1. **Increased purine degradation** - Metabolic stress leads to accelerated ATP breakdown and increased uric acid production 2. **Decreased renal excretion** - Lactic acidosis (from G6P → pyruvate → lactate) competitively inhibits uric acid secretion in renal tubules 3. **Enhanced purine synthesis** - Increased availability of ribose-5-phosphate from pentose phosphate pathway - Classic triad: **Hepatomegaly, hypoglycemia, and lactic acidosis with hyperuricemia** *Type II (Pompe disease)* - Caused by a deficiency of **acid alpha-glucosidase** (acid maltase), leading to glycogen accumulation in **lysosomes**. - Primarily affects the **heart**, **muscles**, and **liver**, but does not cause hyperuricemia. *Type IV (Andersen disease)* - Results from a deficiency of **glycogen branching enzyme**, leading to the formation of abnormal glycogen with long, unbranched chains. - Primarily affects the **liver** and **spleen**, causing cirrhosis and hepatic failure, but not hyperuricemia. *Type III (Cori disease)* - Caused by a deficiency of **glycogen debranching enzyme** (amylo-1,6-glucosidase), leading to abnormal accumulation of glycogen with short outer branches. - Presents with hepatomegaly, hypoglycemia, and muscle weakness, but **hyperuricemia is not a characteristic feature**.
Question 32: Glucose oxidase converts glucose to?
- A. Glucuronic acid
- B. Galactonic acid
- C. Gluconic acid (Correct Answer)
- D. Iduronic acid
Explanation: ***Gluconic acid*** - **Glucose oxidase** specifically catalyzes the oxidation of glucose, producing **gluconic acid** and hydrogen peroxide. - This reaction forms the basis for many common **glucose diagnostic tests**, such as those used in blood glucose monitors. *Glucuronic acid* - **Glucuronic acid** is formed from the oxidation of glucose at carbon 6, typically through the **uronic acid pathway**. - It is known for its role in **detoxification** and conjugation reactions in the liver, not as a direct product of glucose oxidase. *Galactonic acid* - **Galactonic acid** is an oxidized form of galactose, a different monosaccharide from glucose. - Its formation is not associated with the action of **glucose oxidase**, an enzyme specific to glucose. *Iduronic acid* - **Iduronic acid** is a C5 epimer of glucuronic acid and is a common component of various **glycosaminoglycans** like dermatan sulfate and heparan sulfate. - It is not produced by the action of **glucose oxidase** on glucose.
Question 33: Apoenzyme is ?
- A. Protein moiety (Correct Answer)
- B. Organic cofactor
- C. Inactive enzyme component
- D. Non-protein component required for enzyme activity
Explanation: ***Protein moiety*** - An **apoenzyme** is the **protein component of an enzyme** that is catalytically inactive by itself. - It requires a **non-protein cofactor** (either an inorganic ion or an organic molecule) to become active. *Organic cofactor* - An **organic cofactor** is also known as a **coenzyme**, which binds to the apoenzyme to form a functional holoenzyme. - While essential for enzyme activity, the apoenzyme itself is the protein part, not the organic cofactor. *Inactive enzyme component* - While an apoenzyme is **inactive on its own**, this description is too broad and doesn't specify its chemical nature. - It is specifically the **protein component** that is inactive until bound to its cofactor. *Non-protein component required for enzyme activity* - This describes a **cofactor** (either inorganic or organic), not the apoenzyme itself. - The apoenzyme is the **protein portion**, which *requires* the non-protein component for activity.
Question 34: Fluoroacetate inhibits?
- A. Citrate synthase
- B. Succinate dehydrogenase
- C. Alpha-ketoglutarate dehydrogenase
- D. Aconitase (Correct Answer)
Explanation: ***Aconitase*** - **Fluoroacetate** is metabolically converted to **fluorocitrate**, which is a potent competitive inhibitor of **aconitase**. - **Aconitase** is the enzyme responsible for converting **citrate to isocitrate** in the **Krebs cycle**, and its inhibition blocks the cycle. *Citrate synthase* - This enzyme is responsible for the formation of **citrate** from **acetyl-CoA** and **oxaloacetate**. - While fluoroacetate indirectly affects the cycle, it does not directly inhibit **citrate synthase**. *Succinate dehydrogenase* - This enzyme is part of the **Krebs cycle** and the **electron transport chain**, converting **succinate to fumarate**. - **Malonate** is a competitive inhibitor of succinate dehydrogenase, not **fluoroacetate**. *Alpha-ketoglutarate dehydrogenase* - This enzyme catalyzes the conversion of **alpha-ketoglutarate to succinyl-CoA** in the **Krebs cycle**. - Specific inhibitors of this enzyme include **arsenite** and **mercury compounds**, but not fluoroacetate.
Question 35: Which of the following is required for fatty acid synthesis ?
- A. NADPH (Correct Answer)
- B. NADH
- C. FADH₂
- D. None of the options
Explanation: ***NADPH*** - **NADPH** is crucial for fatty acid synthesis, providing the **reducing power** needed for the successive reduction steps. - The enzymes involved, such as **fatty acid synthase**, utilize **NADPH** for the conversion of keto groups to hydroxyl groups and then to saturated methylene groups. *NADH* - **NADH** plays a primary role in **oxidative phosphorylation** and the electron transport chain to generate ATP. - It is generally produced during **catabolic reactions** and is not primarily used as a reducing agent in anabolic processes like fatty acid synthesis. *FADH* - **FADH2** (reduced form of FAD, not FADH) is a coenzyme involved in redox reactions, particularly in the **Krebs cycle** and beta-oxidation of fatty acids. - Like NADH, it is mostly involved in **catabolic processes** that generate energy, rather than anabolic processes requiring reducing equivalents for synthesis. *None of the options* - This option is incorrect because **NADPH** is indeed required for fatty acid synthesis, serving as the essential reducing agent. - The other coenzymes mentioned (NADH, FADH) have different metabolic roles, primarily in energy production rather than biosynthesis.
Question 36: Which hormone inhibits hormone-sensitive lipase?
- A. Insulin (Correct Answer)
- B. GH
- C. ACTH
- D. Thyroid hormone
Explanation: ***Insulin*** - **Insulin** is a key anabolic hormone that promotes energy storage and inhibits catabolic processes, including the breakdown of triglycerides. - It directly inhibits **hormone-sensitive lipase (HSL)** activity, thus reducing the release of free fatty acids from adipose tissue. *Thyroid hormone* - **Thyroid hormones** (T3 and T4) generally promote catabolism and increase metabolic rate, including the mobilization of lipids. - They tend to **stimulate rather than inhibit** hormone-sensitive lipase expression and activity. *GH* - **Growth hormone (GH)** has lipolytic effects, meaning it promotes the breakdown of fats to provide energy. - GH typically **stimulates HSL activity** and increases the release of free fatty acids from adipocytes. *ACTH* - **Adrenocorticotropic hormone (ACTH)** primarily stimulates the adrenal cortex to produce cortisol. - **Cortisol** can have lipolytic effects in certain contexts and does not directly inhibit HSL; instead, catecholamines act as direct stimulators of HSL.
Question 37: What is the characteristic nitrogenous product of lecithin hydrolysis?
- A. Fatty acids
- B. Choline (Correct Answer)
- C. Glucose
- D. Phosphoric acid
Explanation: ***Choline*** - Lecithin is a type of **phospholipid** called **phosphatidylcholine**, meaning its head group contains choline. - Therefore, during hydrolysis, the **choline** component is released as the characteristic nitrogenous product. *Glucose* - **Glucose** is a simple sugar and a carbohydrate, not a component of lecithin. - It is a primary source of **energy** for cells but is not released during lipid hydrolysis. *Fatty acids* - While **fatty acids** are indeed components of lecithin (two fatty acid chains are attached to the glycerol backbone), they are not nitrogenous. - Fatty acids are **hydrophobic hydrocarbon chains** that make up a significant part of the lipid structure. *Phosphoric acid* - **Phosphoric acid** (or phosphate) is also a component of lecithin, connecting the glycerol backbone to the choline group. - However, it is an **inorganic acid** and does not contain nitrogen.
Question 38: What is the cofactor required for the enzyme xanthine oxidase?
- A. Selenium
- B. Zinc
- C. Molybdenum (Correct Answer)
- D. Magnesium
Explanation: ***Molybdenum*** - **Xanthine oxidase** is a key enzyme in **purine metabolism**, responsible for the oxidation of **hypoxanthine to xanthine** and further to **uric acid**. - **Molybdenum** is an essential trace element that serves as a **cofactor** for several enzymes, including xanthine oxidase, where it helps facilitate electron transfer reactions. *Selenium* - **Selenium** is a cofactor for **glutathione peroxidase**, an enzyme involved in antioxidant defense. - It is not directly involved in the function of **xanthine oxidase**. *Zinc* - **Zinc** is a cofactor for a wide range of enzymes, including **carbonic anhydrase** and **alcohol dehydrogenase**. - It does not serve as a cofactor for **xanthine oxidase**. *Magnesium* - **Magnesium** is a critical cofactor for many enzymes, particularly those involved in **ATP hydrolysis and synthesis** and **DNA/RNA synthesis**. - It is not a cofactor for **xanthine oxidase**.
Question 39: NADH via glycerophosphate shunt makes how many ATP?
- A. 1
- B. 4
- C. 2 (Correct Answer)
- D. 3
Explanation: ***2*** - The **glycerol phosphate shuttle** transfers electrons from **cytosolic NADH** to **FAD** in the mitochondrial electron transport chain. - Each **FADH2** molecule produced then enters the electron transport chain at **Complex II**, ultimately leading to the generation of approximately **2 ATP** molecules. *1* - This option would be correct if the electrons were transferred to a molecule that yields only **one ATP** equivalent, which is not the case for **FADH2**. - No direct mechanism in a shunt generates exactly one ATP per NADH equivalent. *3* - This value represents the ATP yield from **NADH** when it directly enters the electron transport chain via the **malate-aspartate shuttle**, not the **glycerophosphate shuttle**. - The **glycerophosphate shuttle** is less efficient than the **malate-aspartate shuttle**. *4* - This number is not a standard ATP yield for either **NADH** or **FADH2** in the electron transport chain. - The maximum yield for NADH is typically considered to be 2.5 or 3 ATP, and for FADH2 is 1.5 or 2 ATP, depending on the shuttle and precise calculations.
Question 40: Which of the following pairs of compounds has the highest standard reduction potential?
- A. NADH/NAD+
- B. Succinate/Fumarate
- C. Ubiquinone/Ubiquinol
- D. Fe³⁺/Fe²⁺ (Correct Answer)
Explanation: ***Fe³⁺/Fe²⁺*** - The **Fe³⁺/Fe²⁺ couple** has a **standard reduction potential (E'0)** of **+0.77 V**, making it the highest among the given options. - A higher positive E'0 indicates a stronger tendency for the oxidized form to accept electrons and be reduced. *NADH/NAD+* - The **NADH/NAD+ couple** has a **standard reduction potential** of **-0.32 V**, indicating it is a strong reducing agent. - Its negative reduction potential means it readily donates electrons during metabolic processes. *Succinate/Fumarate* - The **succinate/fumarate couple** has a **standard reduction potential** of **+0.03 V**. - This pair is involved in the **TCA cycle**, where succinate is oxidized to fumarate, releasing electrons. *Ubiquinone/Ubiquinol* - The **ubiquinone/ubiquinol couple** has a **standard reduction potential** varying around **+0.05 to +0.10 V**, depending on the specific state. - It acts as a mobile electron carrier in the **electron transport chain**, accepting electrons from NADH and FADH2.